1. Home
  2. CRSP vs GNTX Comparison

CRSP vs GNTX Comparison

Compare CRSP & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • GNTX
  • Stock Information
  • Founded
  • CRSP 2013
  • GNTX 1974
  • Country
  • CRSP Switzerland
  • GNTX United States
  • Employees
  • CRSP N/A
  • GNTX N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • GNTX Auto Parts:O.E.M.
  • Sector
  • CRSP Health Care
  • GNTX Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • GNTX Nasdaq
  • Market Cap
  • CRSP 4.9B
  • GNTX 4.8B
  • IPO Year
  • CRSP 2016
  • GNTX N/A
  • Fundamental
  • Price
  • CRSP $57.68
  • GNTX $27.03
  • Analyst Decision
  • CRSP Buy
  • GNTX Buy
  • Analyst Count
  • CRSP 16
  • GNTX 7
  • Target Price
  • CRSP $70.73
  • GNTX $29.14
  • AVG Volume (30 Days)
  • CRSP 3.7M
  • GNTX 2.8M
  • Earning Date
  • CRSP 08-04-2025
  • GNTX 07-25-2025
  • Dividend Yield
  • CRSP N/A
  • GNTX 1.75%
  • EPS Growth
  • CRSP N/A
  • GNTX N/A
  • EPS
  • CRSP N/A
  • GNTX 1.78
  • Revenue
  • CRSP $37,675,000.00
  • GNTX $2,384,794,644.00
  • Revenue This Year
  • CRSP $28.31
  • GNTX $7.38
  • Revenue Next Year
  • CRSP $268.05
  • GNTX $7.17
  • P/E Ratio
  • CRSP N/A
  • GNTX $15.46
  • Revenue Growth
  • CRSP N/A
  • GNTX 2.43
  • 52 Week Low
  • CRSP $30.04
  • GNTX $20.28
  • 52 Week High
  • CRSP $71.13
  • GNTX $31.75
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 52.32
  • GNTX 72.86
  • Support Level
  • CRSP $61.13
  • GNTX $23.35
  • Resistance Level
  • CRSP $69.58
  • GNTX $27.98
  • Average True Range (ATR)
  • CRSP 3.89
  • GNTX 0.58
  • MACD
  • CRSP -0.71
  • GNTX 0.46
  • Stochastic Oscillator
  • CRSP 28.46
  • GNTX 82.21

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About GNTX Gentex Corporation

Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.

Share on Social Networks: